Description

Semaglutide is a GLP-1 receptor agonist available in oral and injectable formulations. FDA-approved Rybelsus tablets are available in 3 mg, 7 mg and 14 mg strengths for adults with type 2 diabetes, with additional cardiovascular-risk language in the current prescribing information.

What are Semaglutide 3 mg Tablets?
Semaglutide 3 mg is an oral GLP-1 receptor agonist strength. In the FDA-approved Rybelsus 3 mg / 7 mg / 14 mg regimen, 3 mg is taken once daily for the first 30 days as a starting dose and is not effective for glycemic control. Follow the exact product label and prescription.

How Oral Semaglutide Works
Semaglutide activates GLP-1 receptors involved in glucose-dependent insulin secretion, glucagon regulation, gastric emptying and appetite signaling.

Role of the 3 mg Strength
For FDA-approved Rybelsus using the 3 mg / 7 mg / 14 mg regimen, 3 mg is the introductory dose for Days 1–30. The FDA labeling states that this starting dose is not effective for glycemic control. On Day 31, the labeled regimen increases to 7 mg once daily. This information should not be used to identify or dose a different oral semaglutide product.

How FDA-Approved Rybelsus Is Taken
Current U.S. prescribing information instructs patients to take Rybelsus on an empty stomach in the morning with up to 4 ounces of water, swallow the tablet whole and wait at least 30 minutes before eating, drinking other beverages or taking other oral medicines. Do not apply these directions to a differently formulated oral semaglutide product unless its label confirms the same instructions.

Important Formulation Note
Semaglutide tablets are not automatically interchangeable on a milligram-to-milligram basis across different formulations. Always verify the brand, formulation and strength on the actual package.

Important Safety Information
Semaglutide is a GLP-1 receptor agonist and is not appropriate for every patient. Approved semaglutide products carry important warnings and contraindications. A healthcare professional should review the patient’s medical history, current medicines and treatment goals before use.

Common adverse reactions reported with approved semaglutide products are mainly gastrointestinal and can include nausea, vomiting, diarrhea, abdominal pain and constipation. Serious reactions can also occur, including pancreatitis, gallbladder problems, kidney injury related to volume depletion, severe gastrointestinal reactions, hypersensitivity reactions and complications of diabetic retinopathy in some patients.

Approved semaglutide labeling includes a boxed warning concerning the risk of thyroid C-cell tumors observed in rodents. Semaglutide products are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The relevance of the rodent findings to humans has not been established.

Tell your healthcare professional about planned surgery or procedures requiring general anesthesia or deep sedation, and discuss pregnancy or plans for pregnancy. This summary is not a substitute for the complete prescribing information for the exact product supplied.

Who Should Speak With a Healthcare Professional Before Use?

• Anyone considering semaglutide should have the exact product, indication and dose assessed by a qualified healthcare professional.
• Discuss a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, previous pancreatitis, gallbladder disease, kidney problems, severe gastrointestinal disease, diabetic retinopathy and serious allergies.
• Tell the prescriber about insulin, sulfonylureas and other medicines that can affect blood glucose, as well as other oral medicines when using oral semaglutide.
• Discuss pregnancy, plans for pregnancy or breastfeeding before treatment. Current FDA labeling advises discontinuation of semaglutide at least 2 months before a planned pregnancy because of its long washout period.
• Tell healthcare providers about semaglutide before planned surgery or deep sedation because GLP-1 receptor agonists delay gastric emptying and pulmonary aspiration has been reported.

The information on this page is provided for general educational and product-information purposes and is not medical advice, diagnosis or a substitute for the prescribing information supplied with the medication. Semaglutide is a prescription medicine and may not be appropriate for everyone. Always follow the exact product label and instructions from a licensed healthcare professional. Seek urgent medical care for a suspected medical emergency.